NSABP Objects to “Closed Process” For Review Of P-4 Breast Cancer Chemoprevention Trial.
NCI Barred PI Wolmark And Its Own Prevention Staff From Ad Hod Meeting.
NCI Director To Decide Fate Of P-4 After NCAB Meeting In June.
Paul Goss, Patricia Ganz Discuss Breast Cancer Prevention Trials.
Aranesp Study Finds No Difference In Survival Or Progression In Small-Cell Lung Cancer.
Trending Stories
- Senators slam Bhattacharya for deflecting responsibility for NIH cuts, upheaval
Susan Collins: Trump’s 40% cut is “so disturbing” - The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it” - In the Headlines: Missing record of NCAB meetings restored to NIH website
- Insights from ASCO 2025: Real-world evidence drives clinical decision-making
- In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times
“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.”